This phase II trial is trying to understand whether using a type of immunotherapy (Nivolumab) before starting standard chemotherapy will have a different effect on reducing tumour size for patients with early stage triple negative breast cancer, compared to if the immunotherapy and chemotherapy were given at the same time.
This trial is treating patients with triple negative breast cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in “window” or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancers
Breast Cancer Trials
Eligible patients will be randomised to receive (1) Nivolumab alone for two weeks, followed by Nivolumab + Carboplatin + Paclitaxel for a further 12 weeks, followed by surgery; or (2) Nivolumab + Carboplatin + Paclitaxel for 12 weeks.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More